FGF23 is increased in patients with primary hyperparathyroidism or activating mutations of PTH or the PTH receptor and by continuous PTH infusion, but it is decreased by intermittent PTH infusion to promote bone anabolism and, sometimes, in hypoparathyroidism. The gene discussed is PTH; the disease is primary hyperparathyroidism.